What's Going On With Johnson and Johnson Shares Friday?
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for RYBREVANT in combination with platinum-based chemotherapy.
強生（紐交所：JNJ）股票在週五出現趨勢。在上週，這家藥品公司宣佈了兩項臨床試驗的積極結果，並獲得加拿大衛生部批准與基於鉑金的化療藥物RYBREVANt聯合使用。
The Details: The first of the two clinical trials is a Phase 3 study regarding the use of nipocalimab for patients with generalized myasthenia gravis.
這兩項臨床試驗中的第一項是一項III期研究，研究nipocalimab用於廣泛性重症肌無力患者的使用。
In the first trial, patients who received nipocalimab alongside standard treatment over the course of 24 weeks achieved superiority over the placebo group in activities of daily living. The study achieved its primary endpoint as well as secondary endpoints, such as improvement in strength and function of certain muscle groups.
在第一項試驗中，在24周的標準治療過程中，接受nipocalimab治療的患者的日常生活活動優於安慰劑組。該研究達到了主要終點和次要終點，例如某些肌肉群的力量和功能改善。
The second study was the Phase 3 CARTITUDE-4 study evaluating CARVYKTI against standard therapies for patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. The interim analysis demonstrated a notable and statistically significant enhancement in overall survival for patients who received CARVYKTI versus standard treatments.
第二項研究是第III期CARTITUDE-4研究，評估CARVYKTI與一線治療後復發或鐮刀狀細胞貧血耐藥性多發性骨髓瘤的標準治療對比。中期分析表明，接受CARVYKTI治療的患者相比標準治療組在總體生存方面有顯著的統計學顯著性提高。
"CARVYKTI, a one-time infusion, is now the first cell therapy to significantly improve overall survival versus standard of care for patients with myeloma as early as second line," said Jordan Schecter, M.D., vice president, disease area leader, multiple myeloma, Johnson & Johnson Innovative Medicine.
“CARVYKTI作爲一次性輸注，現在是針對骨髓瘤患者早期二線治療而不是標準護理的首個可顯著改善總體生存率的細胞療法，”強生創新藥品公司多發性骨髓瘤疾病區域領袖、副總裁喬丹·謝克特博士說。
On Wednesday, Health Canada authorized the use of RYBREVANT in combination with platinum-based chemotherapy for the treatment of certain non-small cell lung cancers.
週三，加拿大衛生部批准RYBREVANt與基於鉑金的化療藥物聯合用於某些非小細胞肺癌的治療。
Analyst Changes: Over the past week, one analyst has issued a price target adjustment.
分析師變動：在過去的一週中，有分析師發佈了價格目標調整。
- On Monday, Cantor Fitzgerald analyst Louise Chen reiterated Johnson & Johnson with a Overweight and maintained $215 price target.
- 週一，卡內基菲茨傑拉德分析師路易絲·陳重申對強生報告評級爲超配，並維持215美元的價格目標。
Related Link: Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
相關鏈接：激進投資者在運動醫學公司Smith＆Nephew中入股，股價飆升。
JNJ Price Action: At the time of writing, Johnson and Johnson stock is trading .57% lower at $144.85, according to data from Benzinga Pro.
JNJ價格走勢：截至撰寫時，強生股票按$144.85交易，降低了0.57％，數據來源於Benzinga Pro。
Image: Photo via Shutterstock
圖像：通過shutterstock拍攝
譯文內容由第三人軟體翻譯。